Progress in the Development of Vision Prostheses

Matthaei, Mario; Zeitz, Oliver; Keserü, M.; Wagenfeld, Lars; Hornig, R.; Post, Nils; Richard, Gisbert

doi:10.1159/000318042

Cited by 29 publications

(27 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Any neuronal remodelling that does occur has not yet been shown to definitely affect vision processing ability 1 2. On this basis, vision-restoring implants have been developed to interface with various parts of the visual pathway, particularly the retina 3 – 5. Current retinal implants permit rudimentary greyscale light perception, allowing patients to perform simple visual tasks and independently navigate 6 7…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Retinal implants: a systematic review: Table 1

2014

View full text Add to dashboard Cite

Retinal implants present an innovative way of restoring sight in degenerative retinal diseases. Previous reviews of research progress were written by groups developing their own devices. This systematic review objectively compares selected models by examining publications describing five representative retinal prostheses: Argus II, Boston Retinal Implant Project, Epi-Ret 3, Intelligent Medical Implants (IMI) and Alpha-IMS (Retina Implant AG). Publications were analysed using three criteria for interim success: clinical availability, vision restoration potential and long-term biocompatibility. Clinical availability: Argus II is the only device with FDA approval. Argus II and Alpha-IMS have both received the European CE Marking. All others are in clinical trials, except the Boston Retinal Implant, which is in animal studies. Vision restoration: resolution theoretically correlates with electrode number. Among devices with external cameras, the Boston Retinal Implant leads with 100 electrodes, followed by Argus II with 60 electrodes and visual acuity of 20/1262. Instead of an external camera, Alpha-IMS uses a photodiode system dependent on natural eye movements and can deliver visual acuity up to 20/546. Long-term compatibility: IMI offers iterative learning; Epi-Ret 3 is a fully intraocular device; Alpha-IMS uses intraocular photosensitive elements. Merging the results of these three criteria, Alpha-IMS is the most likely to achieve long-term success decades later, beyond current clinical availability.

show abstract

Section: Introductionmentioning

confidence: 99%

“…To date, several reviews of retinal implants have been published 1 3 5. However, they have been authored by groups developing their own devices.…”

Section: Introductionmentioning

confidence: 99%

Retinal implants: a systematic review: Table 1

2014

View full text Add to dashboard Cite

show abstract

“…The combined use of anti-VEGFs with steroids, such as triamcinolone acetonide or dexamethasone, showed a temporary improvement in vision and reduction in macular thickness in patients for whom monotherapy with intravitreal bevacizumab injection was unsuccessful [54,55]. …”

Section: Recent Researchmentioning

confidence: 99%

Current Choroidal Neovascularization Treatment

Liu

Ye²,

Wen³

2013

Ophthalmologica

View full text Add to dashboard Cite

Purpose: This paper aims to describe the current situation of choroidal neovascularization (CNV) treatment. Procedures: MEDLINE (2001-2013) was searched for original research studies (phase I, II, III), abstracts and review articles concerning CNV therapy, and other related articles. Selected information from related websites was also included. Results: The management of CNV was developed through laser photocoagulation and photodynamic therapy, and has now evolved into anti-vascular endothelial growth factor (VEGF) use. Patients have achieved better visual acuity and toleration with the development of this therapy strategy. Combination therapy appears to offer a reduced retreatment frequency and long-term maintenance of the benefit with appropriate combination. Other treatment explorations with anti-inflammation and anti-VEGF are also ongoing. Conclusions: Anti-VEGF monotherapy has become the first treatment for CNV patients. The investigation of other therapy strategies may prolong the interval of treatment and provide alternatives to CNV treatment.

show abstract

“…The absence of visual data greatly decreases quality of life. Although preventive treatments exist, there is no treatment method for complete vision loss caused by retinal diseases such as age-related macular degeneration, retinal detachment, and retinitis pigmentosa, which lead to photoreceptor loss [1][2][3]. In recent years, by overcoming this handicap, to create useful vision, many studies have been started to develop artificial vision systems (or visual prostheses) that electrically stimulate the remaining retinal ganglion cells [1,[4][5][6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

“…After this step, these encoded pulses are sent to the targeted place of the visual pathway on which the microelectrode matrix placed. Based on electrode placement strategies, visual prostheses can be grouped into 3 main categories, as the visual cortex, optic nerve, and retinal implants [1,2]. Due to the ease of electrode placement and less surgical risks, many studies are focused on the retina implant system.…”

Section: Introductionmentioning

confidence: 99%

Spatiotemporal realization of an artificial retina model and performance evaluation through ISI- and spike count-based image reconstruction methods

Karagöz¹,

Özden²

2014

Turk J Elec Eng & Comp Sci

View full text Add to dashboard Cite

Development of an artificial retina model that can mimic the biologic retina is a highly challenging task and this task is an important step in the development of a visual prosthesis. The receptive field structure of the retina layer is usually modeled as a 2D difference of Gaussian (DOG) filter profile. In the present study, as a different approach, a retina model including a 3D 2-stage DOG filter (3D-ADOG) that has an adaptively changing bandwidth with respect to the local image statistic is developed. Using this modeling, the adaptive image processing of the retina can be realized. The contribution of the developed model in terms of the image quality is evaluated via simulation studies using test images. The first simulation results, including only the spike count-based reconstruction for a test video sequence, were previously published. In this study, in addition to the spike count-based reconstruction, the interspike interval measure is also used in the simulation study. The reconstruction results are compared using the statistical parameters of the mean squared error (MSE), universal quality index (UQI), and histogram similarity ratio (HSR), which characterize the image likelihood. To evaluate the performance of the model versus time, time-dependent changes in the MSE, HSR, and UQI parameters are obtained and compared to the standard model. From these results, it is concluded that the 3D-ADOG filter-based retina model preserves the spatial details of the image and produces a larger number of different gray tone levels, which are important for the visual perception of an image, in comparison with the well-known classical DOG filter-based retina model. The retina implant systems based on this model can provide better visual perception for implant recipients.

show abstract

Progress in the Development of Vision Prostheses

Cited by 29 publications

References 50 publications

Retinal implants: a systematic review: Table 1

Retinal implants: a systematic review: Table 1

Current Choroidal Neovascularization Treatment

Spatiotemporal realization of an artificial retina model and performance evaluation through ISI- and spike count-based image reconstruction methods

Contact Info

Product

Resources

About